Boston Scientific Corporation Stock News

Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for th

Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.

With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Boston Scientific (BSX). But which of these two stocks presents investors with the bet

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Investors looking for stocks in the Medical - Products sector might want to consider either AdaptHealth Corp. (AHCO) or Boston Scientific (BSX). But which of these two stocks is more attractive to val

Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.

The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Boston Scientific said on Friday the U.S. Food and Drug Administration has approved its device to treat a complication of heart disease.

Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Boston Scientific BSX (NYSE: BSX) reported its Q4 results last month, with revenues and earnings comfortably beating the street estimates. The company reported revenue of $3.7 billion and adjusted ear

Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.

Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.

Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.